HUMAN PAPILLOMAVIRUS, L1 PROTEIN VIRUS LIKE PARTICLES

Summary

Human Papillomavirus, L1 Protein Virus Like Particles (CHEMBL6068359) is an approved vaccine component; indicated across 2 conditions including human papilloma virus infection.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Vaccine component
• Indications: 2 conditions
• Clinical trials: 67

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6068359
Name	HUMAN PAPILLOMAVIRUS, L1 PROTEIN VIRUS LIKE PARTICLES
Type	Vaccine component
Max phase	4

Also known as: Cervarix, Gardasil, Gardasil 9, Human papillomavirus, l1 protein virus like particles, Silgard, HUMAN PAPILLOMAVIRUS, L1 PROTEIN VIRUS LIKE PARTICLES

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
human papilloma virus infection	4	MONDO:0005161	EFO:0001668

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 67.

Phase distribution

Phase	Trials
PHASE4	17
PHASE3	17
Not specified	14
PHASE2	11
PHASE1	6
PHASE1/PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04206813	PHASE4	ACTIVE_NOT_RECRUITING	An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen
NCT06052696	PHASE4	NOT_YET_RECRUITING	Adjuvant Nonavalent HPV Vaccination in Women Treated for Vulvar HSIL
NCT06536855	PHASE4	NOT_YET_RECRUITING	Faster Elimination of HPV Infection and Cervical Cancer Using Concomitant HPV Vaccination and HPV Screening: A Demonstration Project in Rwanda
NCT06786429	PHASE4	NOT_YET_RECRUITING	Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.
NCT07314307	PHASE4	ACTIVE_NOT_RECRUITING	Vaccine Effectiveness of One Dose of the Nonavalent Human Papillomavirus (HPV) Vaccine Among Young-adult Women in Sweden Among Women Participating in a Clinical Trial of Concomitant HPV Vaccination and Screening
NCT00534638	PHASE4	COMPLETED	Effectiveness, Safety and Immunogenicity of GSK Biologicals’ HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents
NCT00730847	PHASE4	TERMINATED	A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.
NCT00925288	PHASE4	COMPLETED	Acceptability of Human Papillomavirus (HPV) Vaccine in Female Sex Workers
NCT00956553	PHASE4	COMPLETED	Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls
NCT01082861	PHASE4	TERMINATED	Efficacy and Immunomodulation Study of Simultaneous Human Papillomavirus/ Hepatitis B (HPV/HBV) Vaccination
NCT01386164	PHASE4	COMPLETED	Immune Response to Bivalent and Tetravalent Human Papillomavirus Vaccine in HIV Infected Adults
NCT01824537	PHASE4	COMPLETED	Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study
NCT01914367	PHASE4	COMPLETED	Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®)
NCT02087384	PHASE4	COMPLETED	HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN)
NCT02837926	PHASE4	COMPLETED	Comparing Health Services Interventions for the Prevention of HPV-related Cancer
NCT03105856	PHASE4	COMPLETED	FASTER-Tlalpan Study in Mexico: HPV Vaccination Impact on Cervical Cancer Screening Program
NCT04459221	PHASE4	COMPLETED	Study of the Impact of a School Program Combining - Promotion of HPV Vaccination and HPV Vaccine Offer in Middle School - on Adherence to HPV Vaccination in Middle School Students
NCT03998254	PHASE3	ACTIVE_NOT_RECRUITING	Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)
NCT00092495	PHASE3	COMPLETED	Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)
NCT00092534	PHASE3	COMPLETED	Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)
NCT00196937	PHASE3	COMPLETED	Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals’ HPV-16/18
NCT00294047	PHASE3	COMPLETED	Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older
NCT00481767	PHASE3	COMPLETED	Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals’ Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.
NCT00543543	PHASE3	COMPLETED	Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
NCT00811798	PHASE3	COMPLETED	Safety Study of GSK Biologicals’ HPV Vaccine (GSK-580299) in Healthy Female Subjects.
NCT00964210	PHASE3	COMPLETED	Protecting Young Special Risk Females From Cervical Cancer Through Human Papilloma Virus (HPV) Vaccination
NCT01190176	PHASE3	COMPLETED	Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
NCT01304498	PHASE3	COMPLETED	Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)
NCT01375868	PHASE3	COMPLETED	Effect of Vaccination in Patients With Recurrent Respiratory Papillomatosis
NCT01462357	PHASE3	COMPLETED	Immunogenicity and Safety Study of GlaxoSmithKline Biologicals’ Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck’s Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females
NCT01627561	PHASE3	COMPLETED	Safety and Immunogenicity of GSK Biologicals’ HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old
NCT02114385	PHASE3	COMPLETED	A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)
NCT03431246	PHASE3	COMPLETED	Immunogenicity of One Dose of Gardasil and One Dose of Gardasil-9
NCT05580341	PHASE3	UNKNOWN	Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9
NCT03519464	PHASE2	ACTIVE_NOT_RECRUITING	Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia
NCT07407569	PHASE2	RECRUITING	Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination
NCT00260039	PHASE2	COMPLETED	Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001)
NCT00309166	PHASE2	COMPLETED	Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals’ HPV Vaccine in Young Males.
NCT00513526	PHASE2	COMPLETED	Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection
NCT00518336	PHASE2	COMPLETED	Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).